Market cap
$14 Mln
Market cap
$14 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-21 Mln
ROE
-0.5 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
1.1
Debt to Equity
0.1
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
7,098,740
CFO
$-168.15 Mln
EBITDA
$-193.36 Mln
Net Profit
$-196.22 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Celsion (CLSN)
| -82.1 | -4.6 | -36.4 | -87.1 | -58.2 | -49.2 | -56.6 |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Celsion (CLSN)
| -24.1 | -58.4 | 21.3 | -47.2 | -37.0 | -84.2 | -17.6 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Celsion (CLSN)
|
1.5 | 13.9 | 0.5 | -26.9 | -3,186.4 | -61.4 | -- | 0.2 |
| 74.9 | 9,733.6 | 1,091.0 | 202.3 | 31.6 | 31.3 | 43.4 | 17.1 | |
| 65.4 | 8,216.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 45.1 | 11,658.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.3 | |
| 89.4 | 11,852.6 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 8,209.1 | 1,396.6 | 316.9 | 59.8 | 153.6 | 27.1 | 161.7 | |
| 520.8 | 12,204.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.3 | |
| 415.6 | 14,867.3 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.4 | |
| 107.2 | 8,460.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.8 | |
| 339.3 | 9,538.9 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the... localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey. Read more
Exec. Chairman
Mr. Michael H. Tardugno
Exec. Chairman
Mr. Michael H. Tardugno
Headquarters
Lawrenceville, NJ
Website
The share price of Celsion Corporation (CLSN) is $1.45 (NASDAQ) as of 22-Nov-2022 09:30 EDT. Celsion Corporation (CLSN) has given a return of -58.16% in the last 3 years.
Since, TTM earnings of Celsion Corporation (CLSN) is negative, P/E ratio is not available.
The P/B ratio of Celsion Corporation (CLSN) is 0.24 times as on 22-Nov-2022, a 95 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Celsion Corporation (CLSN) are Rs -- and Rs -- as of 25-Apr-2026.
Celsion Corporation (CLSN) has a market capitalisation of $ 14 Mln as on 22-Nov-2022. As per SEBI classification, it is a company.
Before investing in Celsion Corporation (CLSN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.